Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PIPE Proceeds In Hand, Novavax Looks To Score With Two Late-Stage Flu Vaccines

This article was originally published in The Pink Sheet Daily

Executive Summary

Vaccine-focused biotech says it has sufficient cash to continue business strategy through third-quarter 2009.

You may also be interested in...



Stock Price Increases Suggest Flu-Oriented Biotechs May Capitalize On Differentiation

Companies like Novavax and Dynavax may enjoy improved financial prospects thanks to the way their differentiated approaches to flu therapy could address future outbreaks.

Stock Price Increases Suggest Flu-Oriented Biotechs May Capitalize On Differentiation

Companies like Novavax and Dynavax may enjoy improved financial prospects thanks to the way their differentiated approaches to flu therapy could address future outbreaks.

Novavax Looks To Increase Runway Through Strategic Alliance With India’s Cadila Pharma

A recently announced three-prong partnership with India's Cadila Pharmaceuticals should enable Novavax to pay off $22 million in convertible debt due in July and still have about one year's worth of operating cash, the vaccine maker's chief executive, Rahul Singhvi, said in an interview

Related Content

Topics

UsernamePublicRestriction

Register

PS067052

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel